Generics are the fastest growing segment of the pharmaceutical market and are expected to grow larger as more than $100 billion of branded product revenues will likely be lost to generic competition through 2015. The growth rate for generics is 2.5 times that of the overall market. Over the past few years more than 50% of the U.S. top ten drugs (based on script volume) were generics, and over one-half of the top ten manufacturers were generic manufacturers.
The principals behind Ingenus have substantial experience in the pharmaceutical sector with an acute focus on the supply chain; they have successfully built and managed multiple pharmaceutical related businesses including:
- Specialty/mail order pharmacies
- Retail pharmacies
- Clinical research organizations
- Group purchasing organizations
Having worked for the largest drug wholesalers and run third party pharmaceutical logistics businesses, the principals have developed substantial contacts in the wholesale, retail and mail order pharmacy segments, which collectively represent the largest buyers of generic products in the U.S.
Given these market dynamics combined with managements operating experiences, we are positioning privately held Ingenus to capitalize on the growth of the U.S. generic market and are approaching the industry with a multi-tiered portfolio strategy that includes acquisition, partnering, licensing, and product development. Our core strategy is grounded in thoughtful high value product selection, world class research and development, and sustained strategic partnerships.